TAIPEI (The China Post) – Research-driven German pharmaceutical company Boehringer Ingelheim announced Dec. 18 that Felix Gutsche will succeed David Preston as country managing director of Boehringer Ingelheim T.C.M. (BI T.C.M.), effective Jan. 1, 2019. David Preston will retire on Dec. 31, 2018.
One of the Fastest Growing Regional Operation Units
With his committed services and excellent leadership, David Preston has successfully built Boehringer Ingelheim T.C.M. the fourth largest market and one of the fastest growing regional operation units within the corporation in the past nine years.
BI T.C.M. achieved 1 billion Euro sales in November 2018. Over the years, David was strongly committed to bringing new innovative products and solutions to the market and fostering local talents development through robust people strategy.
Felix Gutsche joined Boehringer Ingelheim in 1997. Amongst other responsibilities, he held various positions in finance as head of controlling as well as CFO in other countries.
He also served as the corporate head of GBS. Prior to his most recent assignment as Integration Lead Animal Health, he served as Corporate Division Head Strategy & Consulting.
Felix brings a wealth of experience across a broad range of functions and businesses. His experience and passion will help him to lead the company towards a bigger success in the future.
“I’m excited to lead the T.C.M. business,” said Felix Gutsche. “T.C.M. is a focus market of Boehringer Ingelheim with great potential. I am looking forward to working with my Chinese colleagues and making continuous efforts in improving health for human and animals in T.C.M.”
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company, therefore, concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health, and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 percent of net sales.
Boehringer Ingelheim, Taiwan has served in Taiwan since 1975 as a healthy issue solution provider with nearly 300 employees and 5 different offices located in the north, central and south Taiwan. With a core business in Human Pharm and Animal Health, we support patients in the area of the respiratory, oncology, diabetes, cardiovascular, Parkinson’s disease, fibrosis disease, HIV and more. We support companion animals and their owners in parasite prevention and the treatment for heart disease, also support Livestock farmers in serval disease prevention, such as porcine reproductive and respiratory syndrome, Newcastle Disease and more.
Boehringer Ingelheim, Taiwan has become the fastest growing and most innovative company within the industry in recent years. Also, Boehringer Ingelheim is the only company received Top Employer Recognition for 4 years in a row in 2016, 2017, 2018 and 2019.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company, therefore, aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com (Corporate Website)
www.boehringer-ingelheim.com.tw | Taiwan Website
www.facebook.com/1985BITW | Social Responsibility Facebook Page
www.facebook.com/2017NewBITWAH | Animal Health Facebook Page
http://annualreport.boehringer-ingelheim.com | 2017 Annual Report
By The China Post staff